FLT3/Axl Inhibitor Gilteritinib (ASP2215) Safe and Active in Relapsed or Refractory AML

May 29-June 2, 2015; Chicago, Illinois
Doses of gilteritinib ≥ 80 mg showed an ORR of 58% in patients with relapsed/refractory AML and the FLT3 mutation.
Format: Microsoft PowerPoint (.ppt)
File Size: 392 KB
Released: June 5, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals, Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

Downloadable slides with expert insights on current therapeutic strategies for early relapsed, refractory multiple myeloma from Clinical Care Options.

Jesús F. San-Miguel, MD, PhD Released: July 15, 2020

Downloadable ExpressPoints summary slides with key points related to the optimal treatment of CML with TKIs, from Clinical Care Options.

person default Prof. Dr. med. Tim Henrik Brümmendorf Jorge Cortes, MD person default Carlo Gambacorti-Passerini, MD Released: July 14, 2020

Gain key insights quickly with this short slideset from CCO on latest developments in the treatment of acute lymphoblastic leukemia

Stéphane de Botton, MD David Marks, MD, PhD Released: July 14, 2020

John Pagel, MD, PhD discusses incorporating telemedicine and other strategies into the care plan for patients with CLL during COVID-19

John Pagel Headshot John Pagel, MD, PhD Released: July 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?